Nonlinear pharmacokinetics of cefadroxil in the rat. 1993

M C García-Carbonell, and L Granero, and F Torres-Molina, and J C Aristorena, and J Chesa-Jiménez, and J M Plá-Delfina, and J E Peris-Ribera
Department of Pharmaceutics, Faculty of Pharmacy, University of Valencia, Spain.

The pharmacokinetics and bioavailability of cefadroxil in the rat were examined after intravenous and oral administration at three doses (2.5, 10, and 15 mg). Cefadroxil disposition kinetics was clearly nonlinear, with an increase in plasma clearance as the dose increased (2.65 +/- 0.55, 3.17 +/- 0.48, and 3.82 +/- 0.39 ml/min for the three doses assayed). This phenomenon was attributed to a saturable renal tubular reabsorption of the antibiotic. After oral administration, the normalized Cmax was lower for the largest dose (4.6 +/- 0.7 micrograms/ml) than for the other two doses (5.5 +/- 0.5 and 5.4 +/- 0.7 micrograms/ml). Renal excretion of cefadroxil in the rat after intravenous and oral administration was investigated at two level doses (2.5 and 15 mg). No significant differences were found between doses or administration routes, and the mean percentage of dose recovered in the urine for the intravenous and oral routes was 80.7 +/- 6.1% and 76.4 +/- 3.7%, respectively. Cefadroxil bioavailability estimated from plasma levels or from the amounts of drug excreted in the urine was high and ranged from 90% to 100%.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D008297 Male Males
D002434 Cefadroxil Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative. 4-Hydroxycephalexin,5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))-,BL-S 578,BL-S578,Bidocef,Cefadroxil Anhydrous,Cefadroxil Monohydrate,Cephadroxyl,Duricef,S-578,S578,Ultracef,4 Hydroxycephalexin,BL S 578,BL S578,BLS 578,BLS578,S 578
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

M C García-Carbonell, and L Granero, and F Torres-Molina, and J C Aristorena, and J Chesa-Jiménez, and J M Plá-Delfina, and J E Peris-Ribera
September 1989, Journal of veterinary pharmacology and therapeutics,
M C García-Carbonell, and L Granero, and F Torres-Molina, and J C Aristorena, and J Chesa-Jiménez, and J M Plá-Delfina, and J E Peris-Ribera
June 1991, Journal of pharmaceutical sciences,
M C García-Carbonell, and L Granero, and F Torres-Molina, and J C Aristorena, and J Chesa-Jiménez, and J M Plá-Delfina, and J E Peris-Ribera
November 1981, International journal of clinical pharmacology, therapy, and toxicology,
M C García-Carbonell, and L Granero, and F Torres-Molina, and J C Aristorena, and J Chesa-Jiménez, and J M Plá-Delfina, and J E Peris-Ribera
November 1980, European journal of clinical pharmacology,
M C García-Carbonell, and L Granero, and F Torres-Molina, and J C Aristorena, and J Chesa-Jiménez, and J M Plá-Delfina, and J E Peris-Ribera
January 1982, Pharmacology,
M C García-Carbonell, and L Granero, and F Torres-Molina, and J C Aristorena, and J Chesa-Jiménez, and J M Plá-Delfina, and J E Peris-Ribera
February 1982, Journal of pharmacokinetics and biopharmaceutics,
M C García-Carbonell, and L Granero, and F Torres-Molina, and J C Aristorena, and J Chesa-Jiménez, and J M Plá-Delfina, and J E Peris-Ribera
February 1982, Antimicrobial agents and chemotherapy,
M C García-Carbonell, and L Granero, and F Torres-Molina, and J C Aristorena, and J Chesa-Jiménez, and J M Plá-Delfina, and J E Peris-Ribera
October 1980, Journal of pharmacokinetics and biopharmaceutics,
M C García-Carbonell, and L Granero, and F Torres-Molina, and J C Aristorena, and J Chesa-Jiménez, and J M Plá-Delfina, and J E Peris-Ribera
September 1982, The Journal of antimicrobial chemotherapy,
M C García-Carbonell, and L Granero, and F Torres-Molina, and J C Aristorena, and J Chesa-Jiménez, and J M Plá-Delfina, and J E Peris-Ribera
September 1985, Journal of veterinary pharmacology and therapeutics,
Copied contents to your clipboard!